Abstract
Purpose:
To evaluate rates of changes per year of central corneal thickness (CCT) after antiglaucomatous drug administration with beta blockers (BB), prostaglandins (PG), and carbonic anhydrase inhibitors (CAI) monotherapy and combined topical antiglaucomatous therapy, in a cohort of patients with ocular hypertension, glaucoma suspects and patients with perimetric glaucoma as compared to normal controls.
Methods:
The study included 130 eyes of 66 normal patients, 121 eyes of 65 patients with ocular hypertension, 105 eyes of 63 patients with suspected glaucoma and 49 eyes of 25 patients with perimetric glaucoma (ClinicalTrials.gov number, NTC00494923). All patients underwent standard automated perimetry, 24-hour intraocular pressure profile, optic disc photography and optical coherence pachymetry (OCP, Heidelberg Engineering, Lübeck, Germany). The cohort was divided into 8 groups based on topical antiglaucomatous medication. Linear regression analysis was conducted to analyze the relationship between CCT and exposure to antiglaucomatous medication over time.
Results:
There was a statistically significant decrease in CCT for eyes treated with PG, and BB+PG+CAI (-2,1 and -4.9µm/year). CCT raised significantly for eyes treated with CAI (+6.5 µm/year). For both untreated eyes and those treated with BB, BB+CAI, BB+PG, PG+CAI no statistically significant rate of change in CCT was observed.
Conclusions:
We recommend regular CCT measurements before and during therapy with PG and PG+BB+CAI and CAI. Follow-up IOP measurements may be underestimated for eyes treated with PG, PG+BB+CAI and overestimated for those treated with CAI if CCT is not measured on a regular basis.
Keywords: 550 imaging/image analysis: clinical •
503 drug toxicity/drug effects •
479 cornea: clinical science